#1 Clinical Trials Search in Europe

Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

↓

Matched clinical trials

  • Study on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors

    Recruiting

    2 1 1 1
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +3

  • Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands

  • Study of Gandotinib for Patients with Myeloproliferative Neoplasms, Myelofibrosis, Essential Thrombocythemia, or Polycythemia Vera

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Spain

  • Study on the Safety and Effectiveness of Fedratinib and Azacitidine for Patients with Accelerated Phase Myelofibrosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Treosulfan, Fludarabine Phosphate, and Thiotepa for Patients with Myelofibrosis Undergoing Haplo-identical Transplantation

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on KER-050 and Ruxolitinib for Patients with Myelofibrosis and Anemia

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Sweden

  • Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Italy

  • Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia France Germany Greece +7